




RealRate

PHARMACEUTICAL 2013

Ayala Pharmaceuticals Inc
Rank 193 of 218

ADVAXIS
IMMUNOTHERAPIES™



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Ayala Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ayala Pharmaceuticals Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 17% points. The greatest weakness of Ayala Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 115% points.

The company's Economic Capital Ratio, given in the ranking table, is 48%, being 173% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	895
Cost of Goods Sold	0
Intangible Assets	2,414
Liabilities, Current	9,340
Liabilities, Non-Current	0
Other Assets	429
Other Compr. Net Income	0
Other Expenses	4,190
Other Liabilities	439
Other Net Income	4,443
Other Revenues	12
Property and Equipment	78
Research and Development	6,646
Selling, General and Administrative Expense	5,689

Output Variable	Value in 1000 USD
Assets	3,816
Liabilities	9,779
Expenses	16,525
Revenues	12
Stockholders Equity	-5,963
Net Income	-12,070
Comprehensive Net Income	-12,070
BaseVar	17,287
ECR before LimitedLiability	-369%
Economic Capital Ratio	48%